Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study

被引：36
|
作者：
Flannery, Kyle [1 ]
Boyd, Marley [2 ]
Black-Shinn, Jenny [2 ]
Robert, Nicholas [2 ]
Kamat, Ashish M. [3 ]
机构：
[1] Merck & Co Inc, Kenilworth, NJ 07033 USA
[2] US Oncol Network McKesson Specialty Hlth, The Woodlands, TX 77380 USA
[3] Univ Texas MD Anderson Canc Ctr, Div Surg, Dept Urol, Houston, TX 77030 USA
来源：
FUTURE ONCOLOGY | 2019年 / 15卷 / 12期
关键词：
bladder cancer; cisplatin eligible; patient outcomes; real-world utilization; treatment patterns; PHASE-II TRIAL; TRANSITIONAL-CELL CARCINOMA; UROTHELIAL CARCINOMA; PACLITAXEL; CISPLATIN; CARBOPLATIN; CHEMOTHERAPY; METHOTREXATE; VINBLASTINE; MULTICENTER;
D O I：
10.2217/fon-2018-0654
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: Investigate the effectiveness of chemotherapy for first-line (1L) treatment of metastatic bladder cancer (mBC). Methods: Retrospective cohort study evaluating treatment patterns/outcomes in 1155 mBC patients receiving initial treatment in the community practice setting from January 2010 to June 2014, and followed through July 2016. Results: The most commonly utilized 1L and second-line (2L) regimens were platinum-based and taxane-based, respectively. Median (95% CI) OS for all patients from 1L initiation was 12.8 months (11.7-14.6), and median OS for all 2L regimens was 9.4 months (8.2-11.1). Conclusion: mBC patients eligible for and who received cis-based regimens experienced better OS results. Poor renal function was a key driver of cis-ineligibility. The various monotherapy and combination chemotherapy regimens in 2L produced relatively short OS outcomes.
引用
收藏
页码：1323 / 1334
页数：12
相关论文
共 50 条
  • [1] Physician reported treatment patterns and outcomes in metastatic bladder cancer in the USA: the CancerMPact® Survey 2020
    Bueno, Ana Paula A.
    Clark, Otavio
    Turnure, Matthew
    Moreira, Eloisa S.
    Chang, Jane
    Hou, Ningqi
    Li, Si
    Kim, Ruth
    Kearney, Mairead
    Kirker, Melissa
    Kanas, Gena
    FUTURE ONCOLOGY, 2024, 20 (10) : 613 - 622
  • [2] A Phase II Study of Gemcitabine and Irinotecan in Patients With Locally Advanced or Metastatic Bladder Cancer
    Chaudhary, Uzair B.
    Verma, Nitin
    Keane, Thomas
    Gudena, Vinay
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (02): : 188 - 193
  • [3] Survival Outcomes Associated with First and Second-Line Palliative Systemic Therapies in Patients with Metastatic Bladder Cancer
    Beigi, Arshia
    Vafaei-Nodeh, Saba
    Huang, Longlong
    Sun, Shaun Z.
    Ko, Jenny J.
    CURRENT ONCOLOGY, 2021, 28 (05) : 3812 - 3824
  • [4] Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands
    Reesink, Daan J.
    van de Garde, Ewoudt M. W.
    van der Nat, Paul
    Somford, Diederik M.
    Los, Maartje
    Horenblas, Simon
    van Melick, Harm H. E.
    WORLD JOURNAL OF UROLOGY, 2022, 40 (06) : 1469 - 1479
  • [5] Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway
    Moller, Christina Tanem
    Tafjord, Gunnar
    Blindheim, Augun
    Berge, Viktor
    Fossa, Sophie
    Andreassen, Bettina Kulle
    SCANDINAVIAN JOURNAL OF UROLOGY, 2023, 58 (01) : 101 - 108
  • [6] Efficacy of chemotherapy on overall survival in metastatic sarcomatoid bladder cancer patients
    Tappero, Stefano
    Sorce, Gabriele
    Panunzio, Andrea
    Hohenhorst, Lukas
    Garcia, Cristina Cano
    Piccinelli, Mattia Luca
    Tian, Zhe
    Parodi, Stefano
    Chun, Felix K. H.
    Graefen, Markus
    Antonelli, Alessandro
    De Cobelli, Ottavio
    Saad, Fred
    Shariat, Shahrokh F.
    Montorsi, Francesco
    Suardi, Nazareno R.
    Borghesi, Marco
    Terrone, Carlo
    Karakiewicz, Pierre I.
    CENTRAL EUROPEAN JOURNAL OF UROLOGY, 2022, 75 (04) : 352 - 356
  • [7] Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study
    Parikh, Mamta
    Pan, Chong-Xian
    Beckett, Laurel A.
    Li, Yueju
    Robles, Daniel A.
    Aujla, Pawandeep K.
    Lara, Primo N., Jr.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (06) : 421 - +
  • [8] Efficacy of Surgery on the Primary Tumour in Patients with Metastatic Bladder Cancer: A Comprehensive Review
    Lim, Amy H.
    Westerman, Mary E.
    Korokovic, Andrea
    Matulay, Justin T.
    Narayan, Vikram M.
    Navai, Neema
    BLADDER CANCER, 2022, 8 (02) : 193 - 209
  • [9] Anticancer maintenance chemotherapy prolonged prognosis of metastatic urothelial carcinoma patients: A single institute retrospective study using propensity score matching
    Yamamoto, Akinaru
    Kawashima, Atsunari
    Uemura, Toshihiro
    Yamamichi, Gaku
    Tomiyama, Eisuke
    Koh, Yoko
    Matsushita, Makoto
    Kato, Taigo
    Hatano, Koji
    Uemura, Motohide
    Imamura, Ryoichi
    Nonomura, Norio
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (11) : 1294 - 1303
  • [10] Percutaneous cryotherapy for metastatic bladder cancer: Experience with 23 patients
    Zhou Liang
    Yao Fei
    Niu Lizhi
    Zeng Jianying
    Zhang Zhikai
    Chen Jibing
    Li Jialiang
    Xu Kecheng
    CRYOBIOLOGY, 2014, 68 (01) : 79 - 83
12345